Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen

Journal of Virology

Volumn 83, Issue 17, 2009, Pages 9013-9017

  Reyes Del Valle, Jorge ^a   Hodge, Gregory ^b   McChesney, Michael B ^b   Cattaneo, Roberto ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INOCULATION; LYMPHOCYTE PROLIFERATION; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; REVACCINATION; RHESUS MONKEY; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION; VIREMIA; VIRUS TITRATION; ANIMAL; BLOOD; GENE VECTOR; GENETICS; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOLOGY; MACACA; METHODOLOGY; MONONUCLEAR CELL; SECRETION; SERODIAGNOSIS;

ANIMALIA; HEPATITIS B VIRUS; MACACA MULATTA; MEASLES VIRUS;

ANIMALS; GENETIC VECTORS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MEASLES VIRUS; NEUTRALIZATION TESTS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIREMIA;

EID: 69249206742     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00906-09     Document Type: Article

References (24)

1. Anonymous. 2004. Hepatitis B vaccines. Wkly. Epidemiol. Rec. 79:255-263.
2. Bauer, T., and W. Jilg. 2006. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24:572-577. (Pubitemid 43017822)
3. Billeter, M. A., H. Y. Naim, and S. A. Udem. 2009. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr. Top. Microbiol. Immunol. 329:129-162.
4. Centers for Disease Control and Prevention. 2008. Implementation of newborn hepatitis B vaccination - worldwide, 2006. MMWR Morb. Mortal. Wkly. Rep. 57:1249-1252.
5. Davis, H. L., M. J. McCluskie, J. L. Gerin, and R. H. Purcell. 1996. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. USA 93:7213-7218.
6. del Valle, J. R., P. Devaux, G. Hodge, N. J. Wegner, M. B. McChesney, and R. Cattaneo. 2007. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J. Virol. 81:10597-10605.
7. Devaux, P., V. von Messling, W. Songsungthong, C. Springfeld, and R. Cattaneo. 2007. Tyrosine 110 in the measles virus phosphoprotein is required to block STAT 1 phosphorylation. Virology 360:72-83. (Pubitemid 46319232)
8. Dobson, S., D. Scheifele, and A. Bell. 1995. Assessment of a universal, school-based hepatitis B vaccination program. JAMA 274:1209-1213.
9. Goldstein, S. T., F. Zhou, S. C. Hadler, B. P. Bell, E. E. Mast, and H. S. Margolis. 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34:1329-1339.
10. Griffiths, U. K., V. S. Korczak, D. Ayalew, and A. Yigzaw. 2009. Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia. Vaccine 27:1426-1432.
11. Huang, L. M., B. L. Chiang, C. Y. Lee, P. I. Lee, W. K. Chi, and M. H. Chang. 1999. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 29:954-959.
12. Keating, G. M., and S. Noble. 2003. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63:1021-1051.
13. Leroux-Roels, G., B. Abraham, M. Fourneau, N. De Clercq, and A. Safary. 2000. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents. Vaccine 19:937-942.
14. Lubeck, M. D., A. R. Davis, M. Chengalvala, R. J. Natuk, J. E. Morin, K. Molnar-Kimber, B. B. Mason, B. M. Bhat, S. Mizutani, P. P. Hung, et al. 1989. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc. Natl. Acad. Sci. USA 86:6763-6767.
15. Martins, C. L., M. L. Garly, C. Bale, A. Rodrigues, H. Ravn, H. C. Whittle, I. M. Lisse, and P. Aaby. 2008. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 337:a661.
16. Mast, E. E., H. S. Margolis, A. E. Fiore, E. W. Brink, S. T. Goldstein, S. A. Wang, L. A. Moyer, B. P. Bell, and M. J. Alter. 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recommend. Rep. 54:1-31.
17. Mast, E. E., and J. W.Ward. 2008. Hepatitis B vaccines, p. 205-241. In S. Plotkin, W. Orenstein, and P. Offit (ed.), Vaccines, 5th ed. Saunders Elsevier, Philadelphia, PA.
18. McChesney, M. B., C. J. Miller, P. A. Rota, Y. D. Zhu, L. Antipa, N. W. Lerche, R. Ahmed, and W. J. Bellini. 1997. Experimental measles. I. Pathogenesis in the normal and the immunized host. Virology 233:74-84.
19. Moss, B., G. L. Smith, J. L. Gerin, and R. H. Purcell. 1984. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature 311:67-69. (Pubitemid 14065282)
20. Mrkic, B., J. Pavlovic, T. Rulicke, P. Volpe, C. J. Buchholz, D. Hourcade, J. P. Atkinson, A. Aguzzi, and R. Cattaneo. 1998. Measles virus spread and pathogenesis in genetically modified mice. J. Virol. 72:7420-7427. (Pubitemid 28377873)
21. Pless, R. P., A. D. Bentsi-Enchill, and P. Duclos. 2003. Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J. Infect. Dis. 187(Suppl. 1):S291-S298.
22. Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M. Huber, C. Dotsch, G. Christiansen, and M. A. Billeter. 1995. Rescue of measles viruses from cloned DNA. EMBO J. 14:5773-5784.
23. Wainwright, R. B., L. R. Bulkow, A. J. Parkinson, C. Zanis, and B. J. McMahon. 1997. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J. Infect. Dis. 175:674-677.
24. Watson, B., D. J. West, A. Chilkatowsky, S. Piercy, and V. A. Ioli. 2001. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 19:3164-3168. (Pubitemid 32324045)